Suppr超能文献

靶向足细胞细胞骨架:从蛋白尿性肾病的发病机制到治疗

Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.

作者信息

Tian Xuefei, Ishibe Shuta

机构信息

Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

出版信息

Nephrol Dial Transplant. 2016 Oct;31(10):1577-83. doi: 10.1093/ndt/gfw021. Epub 2016 Mar 10.

Abstract

Glomerular injury often incites a progression to chronic kidney disease, which affects millions of patients worldwide. Despite our current understanding of this disease's pathogenesis, there is still a lack of therapy available to curtail its progression. However, exciting new data strongly suggest the podocyte-an actin-rich, terminally differentiated epithelial cell that lines the outside of the glomerular filtration barrier-as a therapeutic target. The importance of podocytes in the pathogenesis of human nephrotic syndrome is best characterized by identification of genetic mutations, many of which regulate the actin cytoskeleton. The intricate regulation of the podocyte actin cytoskeleton is fundamental in preserving an intact glomerular filtration barrier, and this knowledge has inspired new research targeting actin-regulating proteins in these cells. This review will shed light on recent findings, which have furthered our understanding of the molecular mechanisms regulating podocyte actin dynamics, as well as discoveries that have therapeutic implications in the treatment of proteinuric kidney disease.

摘要

肾小球损伤常常会促使病情进展为慢性肾病,全球有数百万患者受其影响。尽管我们目前对这种疾病的发病机制有所了解,但仍然缺乏能够遏制其进展的治疗方法。然而,令人振奋的新数据有力地表明,足细胞——一种富含肌动蛋白、终末分化的上皮细胞,排列在肾小球滤过屏障外侧——可作为一个治疗靶点。足细胞在人类肾病综合征发病机制中的重要性,通过基因突变的鉴定得到了最好的体现,其中许多基因突变都调节肌动蛋白细胞骨架。足细胞肌动蛋白细胞骨架的复杂调控对于维持完整的肾小球滤过屏障至关重要,这一认识激发了针对这些细胞中肌动蛋白调节蛋白的新研究。本综述将阐明近期的研究发现,这些发现进一步加深了我们对调节足细胞肌动蛋白动力学分子机制的理解,以及对蛋白尿性肾病治疗具有潜在治疗意义的发现。

相似文献

1
Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.
Nephrol Dial Transplant. 2016 Oct;31(10):1577-83. doi: 10.1093/ndt/gfw021. Epub 2016 Mar 10.
2
Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.
Kidney Int. 2018 Jun;93(6):1298-1307. doi: 10.1016/j.kint.2017.12.028. Epub 2018 Apr 17.
3
Targeting signaling pathways in glomerular diseases.
Curr Opin Nephrol Hypertens. 2012 Jul;21(4):417-27. doi: 10.1097/MNH.0b013e328354a598.
4
The role of the podocyte in albumin filtration.
Nat Rev Nephrol. 2013 Jun;9(6):328-36. doi: 10.1038/nrneph.2013.78. Epub 2013 Apr 23.
5
Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance.
J Clin Invest. 2014 Mar;124(3):1098-113. doi: 10.1172/JCI69778. Epub 2014 Feb 17.
6
The role of podocytes in glomerular pathobiology.
Clin Exp Nephrol. 2003 Dec;7(4):255-9. doi: 10.1007/s10157-003-0259-6.
7
A preclinical overview of emerging therapeutic targets for glomerular diseases.
Expert Opin Ther Targets. 2019 Jul;23(7):593-606. doi: 10.1080/14728222.2019.1626827. Epub 2019 Jun 12.
8
Genetics of nephrotic syndrome: new insights into molecules acting at the glomerular filtration barrier.
J Mol Med (Berl). 2009 Sep;87(9):849-57. doi: 10.1007/s00109-009-0505-9. Epub 2009 Aug 1.
9
Podocyte Geranylgeranyl Transferase Type-I Is Essential for Maintenance of the Glomerular Filtration Barrier.
J Am Soc Nephrol. 2023 Apr 1;34(4):641-655. doi: 10.1681/ASN.0000000000000062. Epub 2023 Jan 13.
10
Podocytes and the quest for precision medicines for kidney diseases.
Pflugers Arch. 2017 Aug;469(7-8):1029-1037. doi: 10.1007/s00424-017-2015-x. Epub 2017 Jun 23.

引用本文的文献

1
GIT ArfGAP2: A Cytoskeletal Safeguard in Podocytes: Suppressing Rac1 to Combat Glomerular Injury.
J Am Soc Nephrol. 2025 Jun 1;36(6):1005-1007. doi: 10.1681/ASN.0000000707. Epub 2025 Apr 18.
2
Digital pathology assessment of kidney glomerular filtration barrier ultrastructure in an animal model of podocytopathy.
Biol Methods Protoc. 2025 Mar 28;10(1):bpaf024. doi: 10.1093/biomethods/bpaf024. eCollection 2025.
5
Cytoskeleton Rearrangement in Podocytopathies: An Update.
Int J Mol Sci. 2024 Jan 4;25(1):647. doi: 10.3390/ijms25010647.
6
Dock5 Deficiency Promotes Proteinuric Kidney Diseases via Modulating Podocyte Lipid Metabolism.
Adv Sci (Weinh). 2024 Mar;11(11):e2306365. doi: 10.1002/advs.202306365. Epub 2023 Dec 31.
7
Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy.
Ren Fail. 2023;45(2):2271986. doi: 10.1080/0886022X.2023.2271986. Epub 2023 Oct 31.
8
tRF-003634 alleviates adriamycin-induced podocyte injury by reducing the stability of TLR4 mRNA.
PLoS One. 2023 Oct 19;18(10):e0293043. doi: 10.1371/journal.pone.0293043. eCollection 2023.
9
Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseases.
J Clin Invest. 2023 Dec 15;133(24):e171237. doi: 10.1172/JCI171237.
10
Protein tyrosine phosphatase 1B is a regulator of alpha-actinin4 in the glomerular podocyte.
Biochim Biophys Acta Mol Cell Res. 2024 Jan;1871(1):119590. doi: 10.1016/j.bbamcr.2023.119590. Epub 2023 Sep 18.

本文引用的文献

1
B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.
J Am Soc Nephrol. 2016 Aug;27(8):2520-7. doi: 10.1681/ASN.2015091002. Epub 2015 Dec 23.
2
Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3β Reinforces the Nrf2 Antioxidant Defense against Podocytopathy.
J Am Soc Nephrol. 2016 Aug;27(8):2289-308. doi: 10.1681/ASN.2015050565. Epub 2015 Dec 8.
3
MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes.
J Clin Invest. 2015 Nov 2;125(11):4091-106. doi: 10.1172/JCI81061. Epub 2015 Oct 5.
4
B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.
J Am Soc Nephrol. 2016 Apr;27(4):999-1005. doi: 10.1681/ASN.2015030266. Epub 2015 Aug 28.
5
Regulation of integrin-mediated adhesions.
Curr Opin Cell Biol. 2015 Oct;36:41-7. doi: 10.1016/j.ceb.2015.06.009. Epub 2015 Jul 17.
6
TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.
Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F393-7. doi: 10.1152/ajprenal.00186.2015. Epub 2015 Jun 17.
10
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
Pediatr Nephrol. 2015 Mar;30(3):469-77. doi: 10.1007/s00467-014-2957-6. Epub 2014 Sep 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验